SDSuzanne W. Dixon

Suzanne W. Dixon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Suzanne W. Dixon has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity

    by Andy Bowe, Mary Hayes, Isha John, Monica Diaz, Suzanne Dixon, Insiya Poonawalla

    Aims: To compare treatment persistence and augmentation in adults with type 2 diabetes initiating glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor therapy, including subgroups with cardiovascular disease and obesity. Materials and Methods: Using Humana Healthcare Research claims data, we identified adults with type 2 diabetes newly initiating GLP‐1 RA or SGLT2i therapy between 1 January, 2018, and 30 June 2022. Eligible patients had >12 months of continuous enrollment before and after the index date (first GLP‐1 RA or SGLT2i claim). Persistence was measured over 12 months post‐index, defined by a therapy gap p p p <0.001) therapy. Cardiovascular and obesity subgroup findings were consistent with overall study findings. A higher percentage of patients were persistent with increasing allowable gap (30‐day: 31.4% vs. 41.1%; 90‐day: 50.1% vs. 59.1%, GLP‐1 RA vs. SGLT2i, respectively). Conclusions: At 1 year, SGLT2i users showed higher persistence and augmentation than GLP‐1 RA users. This may reflect better tolerance, fewer side effects, improved glucose control, preferences for oral medications, lower patient costs, and easier access to SGLT2i medications. Providers may support improved persistence by addressing patient‐specific factors influencing therapy choices.


  • Open Access

    HIV preexposure prophylaxis treatment patterns in a national health plan population

    by Jeremiah Rastegar, Amy Hu, Linda Chung, Lauren Stevens, Suzanne W. Dixon, Phil Schwab, Jeffrey J. Ellis

    Medication nonadherence diminishes the benefits of preexposure prophylaxis (PrEP) for the 1.2 million Americans at risk for HIV exposure. To describe HIV PrEP treatment patterns among Medicare Advantage Prescription Drug (MAPD) plan and commercially insured beneficiaries. This retrospective cohort study identified patients aged 16 to 89 years with at least 1 dispensing of emtricitabine-tenofovir disoproxil fumarate from July 2012, through December 2020, or emtricitabine-tenofovir alafenamide from October 2019 through December 2020, and who were continuously enrolled at least 12 months prior to and following the earliest PrEP claim. Outcomes were HIV PrEP adherence measured by proportion of days covered (PDC) using 2 binary thresholds of 0.60 (4 doses/week) and 0.80 (5-6 doses/week) and duration of index treatment episode, total time on treatment, and total number of prescription fills. The study cohort of 707 (292 MAPD plan, 415 commercial) was predominantly made up of male patients (90.0%) and resided in the South (78.9%) with a mean age of 46.2 years (MAPD plan: 54.5, commercial: 40.4). Both populations engaged in high-risk sexual behavior (All: 18.7%, MAPD plan: 16.8%, commercial: 20.0%) and experienced sexually transmitted infections (All: 3.3%, MAPD plan: 2.1%, commercial: 4.1%). The mean index treatment episode length was 297.0 days (MAPD plan: 283.6, commercial: 306.5). Total time on treatment was 477.3 days (MAPD plan: 450.7, commercial 496.0). At 3 months, 84.9% (MAPD plan: 83.6%, commercial: 85.8%) and at 12 months, 58.7% (MAPD plan: 57.2, commercial: 59.8) of patients achieved a PDC of at least 0.80. At 3 months, 100.0% (MAPD plan: 100.0%, commercial: 100.0%), and at 12 months, 74.3% (MAPD plan: 70.2%, commercial: 76.9%) of patients achieved a PDC of at least 0.60. The cohort had a mean of 16.4 fills of 30 days (MAPD plan: 16.4, commercial: 16.3) supply. There is an opportunity for clinical programs to focus on improving longer-term PrEP adherence among individuals at risk for HIV exposure.


  • Home versus outpatient hospital intravenous immunoglobulin infusion and health care resource utilization

    by Jeremiah Rastegar, Victoria T. Brown, Isha John, Suzanne W. Dixon, Elizabeth Rodman, Jeffrey J. Ellis, Insiya B. Poonawalla


  • Open Access

    Early vs late filling of new heart failure prescription and its association with avoidable hospital admissions

    by Insiya B Poonawalla, Amanda Sutherland, Linda Chung, Suzanne W Dixon, Jeffrey J Ellis

    BACKGROUND: Individuals with heart failure (HF) are at increased risk for hospitalization and readmission after discharge. The impact of timing to new prescription filling on avoidable HF hospitalization is understudied in HF management. The Agency of Healthcare Research and Quality identifies HF-related inpatient admissions as potentially avoidable if they could be managed successfully in outpatient settings. OBJECTIVE: To compare avoidable HF hospitalization rate and all-cause and HF-related costs in patients who were early fillers (≤30 days) vs late fillers (>30 days) of newly prescribed HF medications following an HF-related inpatient stay or emergency department visit. METHODS: This retrospective cohort study used the Humana Research Database to identify patients with at least 1 claim for a new HF medication from January 1, 2018, to June 30, 2019. Eligible patients were enrolled in a Medicare Advantage Prescription Drug plan for at least 12 months pre-index and 6-months post-index (ie, first new HF prescription). Individuals who were early (n = 794) vs late fillers (n = 397) were propensity-score matched in a 2:1 ratio to balance baseline characteristics. A logistic regression model was fitted to compare avoidable HF hospitalization in those who were late fillers vs early fillers. Mean cost differences were compared using paired t-test. Outcomes were measured 6-months post-index. RESULTS: Late fillers had greater odds of experiencing an avoidable HF hospitalization compared with early fillers (odds ratio = 1.65; P = 0.001). Late filling was associated with a 49.5% increase in average all-cause medical costs (P < 0.0001), a 13.6% decrease in average all-cause pharmacy costs (P = 0.0929), and a 39.4% increase in average all-cause total costs (P < 0.0001). HF-related costs showed similar trends. CONCLUSION: Compared with patients who filled their prescription within 30 days of discharge following an HF admission, those who delayed the filling of a new HF prescription experienced increased likelihood of an avoidable readmission, and late filling was associated with increased 6-month total and medical costs. DISCLOSURES: Humana Healthcare Research, Inc., funded the research and article development. No external funds were used in the creation of this work. All authors are/were employees of Humana Inc. and/or Humana Healthcare Research, Inc., at the time of the work.

  • Open Access

    Examining guidelines and new evidence in oncology nutrition: a position paper on gaps and opportunities in multimodal approaches to improve patient care

    by Carla M. Prado, Alessandro Laviano, Chelsia Gillis, Anthony D. Sung, Maureen Gardner, Suayib Yalcin, Suzanne Dixon, Shila M. Newman, Michael D. Bastasch, Abby C. Sauer, et al.

    Malnutrition, muscle loss, and cachexia are prevalent in cancer and remain key challenges in oncology today. These conditions are frequently underrecognized and undertreated and have devastating consequences for patients. Early nutrition screening/assessment and intervention are associated with improved patient outcomes. As a multifaceted disease, cancer requires multimodal care that integrates supportive interventions, specifically nutrition and exercise, to improve nutrient intake, muscle mass, physical functioning, quality of life, and treatment outcomes. An integrated team of healthcare providers that incorporates societies’ recommendations into clinical practice can help achieve the best possible outcomes. A multidisciplinary panel of experts in oncology, nutrition, exercise, and medicine participated in a 2-day virtual roundtable in October 2020 to discuss gaps and opportunities in oncology nutrition, alone and in combination with exercise, relative to current evidence and international societies’ recommendations. The panel recommended five principles to optimize clinical oncology practice: (1) position oncology nutrition at the center of multidisciplinary care; (2) partner with colleagues and administrators to integrate a nutrition care process into the multidisciplinary cancer care approach; (3) screen all patients for malnutrition risk at diagnosis and regularly throughout treatment; (4) combine exercise and nutrition interventions before (e.g., prehabilitation), during, and after treatment as oncology standard of care to optimize nutrition status and muscle mass; and (5) incorporate a patient-centered approach into multidisciplinary care.